The seizure drug that has quietly been working when nothing else has — for roughly three decades — is levetiracetam, most widely known by its brand name Keppra. First approved by the U.S. Food and Drug Administration in 1999, levetiracetam arrived as an add-on therapy for partial-onset seizures and has since become one of the most prescribed antiepileptic drugs in the world. For patients with drug-resistant epilepsy, those who have cycled through older medications like phenytoin, carbamazepine, and valproate without adequate seizure control, levetiracetam has frequently been the agent that finally reduced or eliminated breakthrough episodes. Its unique mechanism of action, which differs fundamentally from nearly every other seizure medication on the market, is a large part of why it succeeds where others fail.
What makes levetiracetam’s longevity remarkable is not just that it works, but that it works across a strikingly broad range of seizure types and patient populations — from newborns in neonatal intensive care units to elderly adults managing seizures alongside dementia. A patient in their seventies with Alzheimer’s disease who develops late-onset epilepsy, for instance, may find that levetiracetam controls their seizures without the heavy sedation or cognitive dulling that older antiepileptics are notorious for. That matters enormously in brain health, where preserving whatever cognitive function remains is just as important as stopping seizures. This article examines why levetiracetam has endured for three decades as a go-to option in treatment-resistant epilepsy, how its mechanism differs from older drugs, what its real limitations are — including psychiatric side effects that can be significant — and what its role looks like in patients with dementia-related seizures. We will also look at newer competitors and whether levetiracetam’s dominance is likely to continue.
Table of Contents
- Why Has This Seizure Drug Worked When Nothing Else Has for 30 Years?
- How Levetiracetam Differs from Older Antiepileptic Drugs — And Where It Falls Short
- Seizures and Dementia — A Connection That Is Often Overlooked
- Starting Levetiracetam in Older Adults — Dosing, Tradeoffs, and Practical Decisions
- When Levetiracetam Is Not the Right Choice
- Brivaracetam and the Next Generation — Refinements, Not Replacements
- The Future of Seizure Treatment in Aging and Dementia
- Conclusion
- Frequently Asked Questions
Why Has This Seizure Drug Worked When Nothing Else Has for 30 Years?
The answer lies in levetiracetam’s mechanism. Unlike traditional antiepileptic drugs, which primarily work by blocking sodium channels or enhancing GABA (the brain’s main inhibitory neurotransmitter), levetiracetam binds to a synaptic vesicle protein called SV2A. this protein plays a role in how neurotransmitters are packaged and released at synapses. By modulating SV2A, levetiracetam appears to dampen excessive neuronal excitability through a pathway that most other seizure drugs do not touch. This means that when sodium channel blockers and GABA enhancers have failed — when neurons have essentially found ways to keep firing despite those interventions — levetiracetam comes at the problem from an entirely different angle. Consider the clinical reality of drug-resistant epilepsy, which historically affects roughly one-third of epilepsy patients. A person might try phenytoin first, then switch to carbamazepine, then add valproate, and still experience multiple seizures per month.
Each of those drugs is working on overlapping pathways. Adding levetiracetam to the mix introduces a genuinely novel mechanism, which is why combination therapy with levetiracetam and a traditional agent often succeeds where stacking two or three traditional agents did not. The drug also has a favorable pharmacokinetic profile: it does not significantly interact with most other medications, it is not heavily metabolized by the liver, and it reaches therapeutic levels relatively quickly. Its track record over nearly three decades has also built an enormous body of real-world evidence. Clinicians are not relying solely on the original clinical trials from the late 1990s. Thousands of studies, case reports, and meta-analyses conducted over the years have confirmed its efficacy across partial-onset seizures, generalized tonic-clonic seizures, and myoclonic seizures. That volume of data gives neurologists a confidence with levetiracetam that newer drugs, however promising, have not yet earned.
How Levetiracetam Differs from Older Antiepileptic Drugs — And Where It Falls Short
The most consequential difference between levetiracetam and older antiepileptics for brain health is cognitive impact. Drugs like phenobarbital, phenytoin, and topiramate are well documented to cause cognitive slowing, memory impairment, and in some cases measurable declines on neuropsychological testing. For an otherwise healthy 25-year-old, this may be tolerable. For a 72-year-old with mild cognitive impairment or early-stage dementia, adding a medication that further erodes thinking ability can be devastating. Levetiracetam, in clinical studies, has generally shown a neutral-to-mild cognitive profile, meaning it does not typically worsen memory or processing speed to the same degree. However, levetiracetam has a significant and well-known limitation: psychiatric side effects. Irritability, agitation, mood swings, and in some cases frank aggression or depression can emerge, sometimes within the first few weeks of treatment.
Estimates vary, but behavioral side effects have historically been reported in a meaningful minority of patients — some studies place the figure at roughly 10 to 15 percent, though rates differ depending on the population studied. In patients with pre-existing psychiatric conditions, the risk appears to be higher. This is particularly relevant for dementia patients, who may already experience behavioral and psychological symptoms. If a person with Lewy body dementia starts levetiracetam and then becomes severely agitated, it can be difficult to distinguish a drug side effect from disease progression. The practical takeaway is that levetiracetam is not universally benign. Clinicians prescribing it to older adults with cognitive impairment should monitor closely for mood and behavioral changes in the first several weeks. If irritability or aggression appears, the response is typically dose reduction or switching to an alternative — brivaracetam, a newer relative of levetiracetam with a potentially better psychiatric profile, is sometimes used in this situation, though the evidence base is still developing.
Seizures and Dementia — A Connection That Is Often Overlooked
The intersection of seizures and dementia is more common than most people realize, and it is an area where levetiracetam has become especially important. Research has consistently shown that people with Alzheimer’s disease have a significantly elevated risk of developing epilepsy compared to the general population. Some estimates suggest the risk is five to ten times higher, particularly in early-onset Alzheimer’s. Seizures in dementia patients are also notoriously difficult to recognize because they often present as subtle episodes — brief staring spells, transient confusion, or unexplained fluctuations in cognition — rather than dramatic convulsions. A real-world example illustrates the challenge: a patient with moderate Alzheimer’s disease begins having episodes where they become suddenly unresponsive for 30 to 60 seconds, followed by a period of increased confusion.
The family assumes this is simply the disease getting worse. It may take months before anyone considers that these episodes could be seizures. When an electroencephalogram (EEG) finally reveals epileptiform activity and levetiracetam is started, the episodes decrease and the patient’s baseline cognitive function may even appear to stabilize slightly — not because the drug treats dementia, but because uncontrolled seizures were making cognition worse. This underscores a critical point: in dementia care, unrecognized seizures can masquerade as disease progression. Treating them does not reverse the underlying neurodegeneration, but it can remove an additional burden on an already compromised brain. Levetiracetam’s relatively clean cognitive profile makes it a logical first choice in this population, though the psychiatric side effects discussed earlier demand vigilance.
Starting Levetiracetam in Older Adults — Dosing, Tradeoffs, and Practical Decisions
The standard approach with levetiracetam in elderly patients, particularly those with any degree of cognitive impairment, is to start low and go slow. While younger adults might begin at 500 milligrams twice daily and titrate up to 1,500 milligrams twice daily, older adults often start at 250 milligrams twice daily, with gradual increases based on tolerability and seizure control. Renal function must be considered because levetiracetam is primarily cleared by the kidneys, and kidney function naturally declines with age. Dosing adjustments are necessary if creatinine clearance is reduced. The tradeoff clinicians face is balancing seizure control against side effect burden. A lower dose may be better tolerated but insufficient to control seizures.
A higher dose may eliminate seizures but trigger the irritability or sedation that undermines quality of life. There is no universal right answer — it requires individualized titration, honest communication between the prescriber and the patient’s caregivers, and willingness to adjust course. Compared to alternatives like lamotrigine, which also has a relatively favorable cognitive profile but requires an extremely slow titration over weeks to avoid a potentially serious skin reaction (Stevens-Johnson syndrome), levetiracetam offers the advantage of faster dose escalation when prompt seizure control is needed. Compared to valproate, which is effective but carries risks of tremor, weight gain, and hepatotoxicity in older adults, levetiracetam is generally the safer choice. For caregivers managing a loved one with dementia and new-onset seizures, the practical advice is straightforward: ask the prescribing neurologist specifically about the psychiatric side effects, establish a baseline assessment of mood and behavior before the drug is started, and keep a log of any changes in the first four to six weeks. This makes it far easier to determine whether a behavioral change is drug-related or disease-related.
When Levetiracetam Is Not the Right Choice
Despite its versatility, there are clinical scenarios where levetiracetam is not the best option, and recognizing these is just as important as knowing its strengths. Patients with a history of major depression, suicidal ideation, or severe anxiety disorders may be poor candidates. The FDA has placed a class-wide warning on antiepileptic drugs regarding suicidality risk, and levetiracetam’s specific propensity for mood disturbance makes this warning particularly relevant. If a dementia patient already exhibits significant behavioral disturbances — aggression, psychosis, severe agitation — adding levetiracetam carries a real risk of making those symptoms worse. Another limitation is that levetiracetam, while effective for many seizure types, is not equally effective for all.
Some forms of epilepsy, particularly certain genetic or structural epilepsies, may respond better to specific alternatives. In addition, a small but real subset of patients simply does not respond to levetiracetam at all, even at high doses, because their seizure networks are not driven by mechanisms that SV2A modulation can address. Drug resistance in epilepsy is complex, involving factors like efflux transporter overexpression at the blood-brain barrier that can prevent adequate drug concentrations from reaching the brain. Clinicians should also be cautious about what might be called therapeutic inertia — the tendency to keep a patient on levetiracetam indefinitely because it is familiar and relatively safe, even when seizure control is suboptimal. If a patient is still having seizures on levetiracetam, the right response is to reassess, not simply to increase the dose and hope. Referral to a comprehensive epilepsy center for evaluation, including video-EEG monitoring and possibly surgical candidacy assessment, should always be considered for truly drug-resistant cases.
Brivaracetam and the Next Generation — Refinements, Not Replacements
Brivaracetam, marketed as Briviact, is the most direct successor to levetiracetam. It binds to the same SV2A target but with approximately 15 to 30 times higher affinity, and it was developed in part to address levetiracetam’s psychiatric side effects. Early clinical experience and some comparative studies have suggested that brivaracetam may indeed cause fewer behavioral disturbances, making it an appealing option for patients who responded well to levetiracetam’s seizure control but could not tolerate its mood effects.
However, brivaracetam has a shorter track record and, as of recent reports, has generally been more expensive than generic levetiracetam, which became available after Keppra’s patent expired. Cost matters — particularly for older adults on fixed incomes managing multiple medications. The broader landscape of newer antiepileptic drugs includes agents like cenobamate, which has shown impressive efficacy in drug-resistant focal epilepsy, and fenfluramine, which has a niche role in Dravet syndrome. None of these have displaced levetiracetam as a workhorse antiepileptic, but they have expanded options for patients who do not respond to it.
The Future of Seizure Treatment in Aging and Dementia
Looking ahead, the most exciting developments are not about finding another levetiracetam but about understanding the relationship between seizures and neurodegeneration at a deeper level. Research into subclinical epileptiform activity — abnormal electrical discharges in the brain that do not cause visible seizures but may contribute to cognitive decline — is raising the question of whether antiepileptic treatment could one day be used to slow dementia progression, not just manage overt seizures. Some early clinical trials have explored levetiracetam specifically in this context, looking at whether low-dose treatment in Alzheimer’s patients with subclinical epileptiform activity could improve or stabilize cognition.
The results so far have been mixed and preliminary, and it would be premature to recommend levetiracetam as a dementia treatment. But the hypothesis itself represents a significant shift in thinking: that seizure-like activity in the aging brain may be both a consequence of neurodegeneration and a contributor to it, creating a vicious cycle that antiepileptic therapy might partially interrupt. If future trials confirm this, levetiracetam’s fourth decade of clinical use could look very different from its first three.
Conclusion
Levetiracetam has earned its place as one of the most important antiepileptic drugs of the past three decades through a combination of genuine mechanistic novelty, broad efficacy, a relatively favorable side effect profile compared to older alternatives, and an enormous body of accumulated clinical evidence. For patients with dementia who develop seizures, it is often the most practical first-line choice — effective, reasonably well tolerated cognitively, and manageable in terms of drug interactions. Its psychiatric side effects, particularly irritability and mood changes, are its most significant drawback and require active monitoring, especially in vulnerable populations.
For caregivers and families navigating the overlap of seizures and dementia, the key takeaway is that new-onset seizures in a person with cognitive decline should not simply be dismissed as part of the disease. They are a treatable complication, and treating them can meaningfully improve quality of life. Levetiracetam is not a perfect drug — no medication is — but its three-decade track record demonstrates that it remains one of the most reliable tools available when seizures persist despite other interventions.
Frequently Asked Questions
Can levetiracetam treat dementia itself?
No. Levetiracetam is an antiepileptic drug, not a dementia treatment. However, by controlling seizures that may be worsening cognition in a dementia patient, it can help stabilize function. Research into whether it might slow cognitive decline related to subclinical epileptiform activity is ongoing but not yet conclusive.
What are the most common side effects of levetiracetam in older adults?
The most frequently reported side effects include drowsiness, fatigue, dizziness, and behavioral changes such as irritability, agitation, or mood swings. In older adults, the psychiatric side effects are of particular concern and should be monitored closely, especially in the first several weeks.
How do you tell if a dementia patient is having seizures?
Seizures in dementia often do not look like the dramatic convulsions people expect. They may present as brief staring spells, sudden unresponsiveness, unexplained confusion, or abrupt worsening of cognitive function. If these episodes are recurrent and stereotyped (similar each time), an EEG evaluation should be considered.
Is brand-name Keppra better than generic levetiracetam?
Generic levetiracetam is considered bioequivalent to brand-name Keppra by the FDA and is widely used. Most patients do well on generics. However, some clinicians and patients have reported differences in tolerability when switching between manufacturers, which may relate to inactive ingredients. If a patient is stable on a particular generic formulation, consistency is generally advisable.
Can levetiracetam be stopped abruptly?
No. Like most antiepileptic drugs, levetiracetam should be tapered gradually under medical supervision. Abrupt discontinuation can trigger rebound seizures, including potentially dangerous status epilepticus. Even if the drug is being stopped due to side effects, a gradual taper over one to several weeks is the standard approach.
